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A B S T R A C T
Background
Malaria resistance by the sickle cell trait (genotype HbAS) has served as the prime example of
genetic selection for over half a century. Nevertheless, the mechanism of this resistance
remains the subject of considerable debate. While it probably involves innate factors such as
the reduced ability of Plasmodium falciparum parasites to grow and multiply in HbAS
erythrocytes, recent observations suggest that it might also involve the accelerated acquisition
of malaria-specific immunity.
Methods and Findings
We studied the age-specific protection afforded by HbAS against clinical malaria in children
living on the coast of Kenya. We found that protection increased with age from only 20% in the
first 2 y of life to a maximum of 56% by the age of 10 y, returning thereafter to 30% in
participants greater than 10 y old.
Conclusions
Our observations suggest that malaria protection by HbAS involves the enhancement of not
only innate but also of acquired immunity to the parasite. A better understanding of the
underlying mechanisms might yield important insights into both these processes.
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Introduction
Sickle cell trait (genotype HbAS) confers a high degree of
resistance to severe and complicated malaria [1–4] yet the
precise mechanism remains unknown. To some extent it
almost certainly relates to the peculiar physical or biochem-
ical properties of HbAS red blood cells: invasion, growth, and
development of Plasmodium falciparum parasites are all
reduced in such cells under physiological conditions in vitro
[5,6], and parasite-infected HbAS red blood cells also tend to
sickle [5,7,8], a process that may result in their premature
destruction by the spleen [5,9]. Nevertheless, while such
factors appear to be important, recent observations suggest
that the mechanism might also involve an immune compo-
nent. For example, in a study conducted in Gambia, we found
that the immune recognition of P. falciparum–infected red
blood cells was enhanced in HbAS children [10], and up-
regulation of malaria-speciﬁc cell-mediated immune re-
sponses has also been observed in HbAS individuals in
Sudan [11,12]. While potentially important, such observations
could represent epi-phenomena, rather than proximate
effects of the HbAS red cell phenotype. Establishing whether
or not immune processes are involved may prove useful in
learning about malaria protection more generally. We have
therefore investigated this question by studying the age-
speciﬁc pattern of malaria disease in children living on the
coast of Kenya. We reasoned that if malaria protection by
HbAS was predominantly innate, it should be independent of
malaria exposure and therefore remain constant with age.
Conversely, if immune mechanisms were involved, the degree
of protection should increase with age up until the age when
children generally become functionally immune to malaria,
at which time any additional immunological advantage
should be lost.
Methods
Patients and Methods
The study was conducted in a cohort of children and adults
living within the Ngerenya and Chonyi areas of Kiliﬁ District
on the coast of Kenya as described in detail previously [13,14].
Brieﬂy, participants were recruited from an age-stratiﬁed
population sample weighted towards children less than 10 y
old, and between September 1998 and March 2004 study
participants were monitored by active surveillance for
clinical events with a focus on malaria. Children born into
study households during the course of the program were
recruited at birth, and participants exited from the study if
informed consent was withdrawn, if they moved out of the
study area for more than 2 mo, or if they died. Hemoglobin
types were available for 1,054 of 1,795 total cohort members
who attended periodic cross-sectional surveys conducted
throughout the study. We have previously deﬁned malaria
as a fever (axillary temperature .37.5 8C) in association with
malaria parasitaemia of any density in children less than 1 y
old or at a density of greater than 2,500 parasites/ll in older
children [13]. However, HbAS has a signiﬁcant effect on the
densities of incident malaria infections, and we have no data
that allow us to conﬁrm whether or not this deﬁnition is also
appropriate for such children. For the purposes of this
analysis, we have therefore used a conservative deﬁnition of
malaria—fever in association with a slide positive for blood
stage asexual P. falciparum parasites at any density. Incident
malaria infections were treated with sulphadoxine–pyrimeth-
amine according to local guidelines.
Laboratory Procedures and Statistical Analysis
Blood ﬁlms were stained and examined for malaria para-
sites by standard methods, and haemoglobin types were
characterized by electrophoresis. We compared the incidence
of malaria in HbAS individuals versus individuals without the
sickle cell allele (genotype HbAA) by Poisson regression (with
malaria as the dependent variable) both with and without
adjustments for the following confounding variables: season
(deﬁned as 90-d blocks), study area (Ngerenya or Chonyi),
ethnic group, and age (in 2-y bands until the age of 10 y, older
participants being classiﬁed in the top band as described in
Table 1). Participants were considered not to be at risk of
malaria and were dropped from both numerator and
denominator populations for 21 d after receiving treatment
with an anti-malarial drug. Because all infants are relatively
resistant to malaria during the ﬁrst 3 mo of life [15], we
excluded children less than 3 mo old from our analyses.
Because the study was conducted over a prolonged period,
most participants contributed data to more than one age
stratum. We took account of potential within-person cluster-
ing of malaria events, both within and between age strata, by
using the ‘‘sandwich’’ estimator as described by Armitage and
colleagues [16], which inﬂates conﬁdence intervals and
adjusts signiﬁcance values as appropriate. We have expressed
our comparisons as adjusted incidence rate ratios (IRRs). We
investigated the possibility that age might be acting as an
effect modiﬁer in the association between malaria and
haemoglobin type by comparing models that included or
excluded interaction terms between haemoglobin type and
age using the Wald test. All analyses were conducted using
STATA version 8.0 (StataCorp, Timberlake, London, United
Kingdom).
Ethical permission for the study was granted by the Kenya
Medical Research Institute National Ethical Review Commit-
tee. Individual written informed consent was provided by all
study participants or their parents.
Results
Overall, HbAS was almost 40% protective against mild
clinical malaria (IRR = 0.62; 95% conﬁdence interval 0.51–
0.76; p , 0.001); however, protection appeared to vary with
age, increasing from only 20% to almost 60% over the ﬁrst 10
y of life and returning to around 30% thereafter (Table 1;
Figure 1). A similar pattern was seen when data from each of
the study areas were analyzed separately. Although we were
not able to prove statistically an overall interaction between
age and protection over the full range of ages (v2
5
= 6.46; p =
0.26), the data support the strong impression of acquired
protection with age.
Discussion
The mechanism by which HbAS protects against malaria
has been the subject of speculation for more than 50 y. While
to some extent it probably relates to the physical character-
istics of HbAS erythrocytes, a number of studies suggest that
HbAS may also enhance the acquisition of natural immunity
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[10,17–19]; however, establishing this relationship is difﬁcult
because immunity to malaria is hard to measure.
To date, no single immune response has been described
that reliably predicts protective immunity. As a result,
immunity to malaria is usually deﬁned as the ability to
control new infections to a level at which they fail to reach a
clinical threshold. We therefore reasoned that the best way to
ﬁnd out whether malaria protection by HbAS involves a
signiﬁcant immune component was to see whether protection
varies with age. Of the cohort studies that have been reported
to date, most have involved repeated cross-sectional sampling
rather than active monitoring for clinical events. Moreover,
of the studies that have investigated the genotype-speciﬁc
incidence of mild malaria [10,20–23], all have been either too
small, have involved a restricted age range of participants, or
have been conducted over too short a period to make it
possible to address this important question. Our study is, to
our knowledge, the ﬁrst with sufﬁcient power to observe the
protective effect of HbAS over a broad age range. We found
that HbAS protection increases throughout the ﬁrst 10 y of
life, returning thereafter to baseline. While it is possible that
this observation could result from any factor that both affects
malaria risk and varies with age, accelerated immune
acquisition seems by far the most likely explanation.
So how might HbAS result in the accelerated acquisition of
malaria-speciﬁc immunity? A number of mechanisms have
been proposed. In common with other red cell genetic
defects, enhanced phagocytosis of HbAS erythrocytes in-
fected with ring stage P. falciparum has been demonstrated in
vitro [24], a process that appears to be mediated by a
mechanism essentially similar to that involved in the
phagocytosis of senescent or damaged normal erythrocytes.
Experimental data suggest that this process is initiated by
enhanced oxidant damage to the erythrocyte membrane and
that this leads to the aggregation of band 3 protein and the
binding of autologous IgG and complement [24], a mecha-
nism similar to that previously proposed for a thalassaemia
[25]. It therefore seems plausible that enhanced immunity
could be mediated by the accelerated acquisition of anti-
bodies to altered host antigens expressed on the parasite-
infected red cell surface, such as band 3 protein [26]. On the
other hand, parasite-derived proteins such as the variant
surface antigen P. falciparum erythrocyte membrane protein-1
might represent an alternative target, an hypothesis sup-
ported by the raised titres of antibodies directed towards
variant antigens seen in HbAS children living in Gambia [10].
These mechanisms need not be mutually exclusive.
Figure 1. The IRR for Malaria in HbAS versus HbAA Children by Age and
Genotypic Group
Infants less than 3 mo old were excluded from the baseline group.
DOI: 10.1371/journal.pmed.0020128.g001
Table 1. Incidence of Clinical Malaria by Age and Haemoglobin Type
Age Range
(Years)
Genotype Number of
Participantsa
Child Years
of Follow-Up
Number of
Malaria
Episodesb
Malaria
Incidencec
IRRd (95%
Confidence Interval)
p-Value
All AA 892 1,958.2 3,189 1.74 1.00
AS 162 354.4 362 1.07 0.62 (0.51–0.76) ,0.001
0.25–2 AA 302 290.9 439 1.99 1.00
AS 52 51.4 63 1.52 0.81 (0.53–1.24) 0.337
2–4 AA 417 331.4 704 2.12 1.00
AS 73 56.7 82 1.45 0.69 (0.50–0.95) 0.024
4–6 AA 423 318.4 694 2.18 1.00
AS 81 58.4 75 1.28 0.63 (0.46–0.85) 0.003
6–8 AA 361 273.8 515 1.88 1.00
AS 82 59.3 56 0.94 0.50 (0.36–0.69) ,0.001
8–10 AA 275 190.9 309 1.61 1.00
AS 62 42.4 28 0.66 0.45 (0.30–0.67) ,0.001
10e AA 283 552.8 528 0.96 1.00
AS 48 86.0 58 0.67 0.73 (0.51–1.05) 0.086
a Because this was a longitudinal cohort study, some participants contributed data to more than one age stratum (see text for details).
b See text for definitions.
c Crude incidence of malaria per person-year of observation.
d Adjusted IRRs for malaria in HbAS individuals compared to baseline (HbAA individuals) were calculated individually for each age stratum using a Poisson regression model that included the confounding variables season, study area, ethnic
group, and bed net usage. Confidence intervals and significance values were adjusted to take account of clustering of events within individual participants using the ‘‘sandwich’’ estimator as described by Armitage and colleagues [16].
e All participants greater than 10 y old were considered functionally immune and were therefore included as a single category. This group included participants 10–84 y old.
DOI: 10.1371/journal.pmed.0020128.t001
PLoS Medicine | www.plosmedicine.org May 2005 | Volume 2 | Issue 5 | e1280443
Malaria Protection by the Sickle Cell Trait
As an alternative explanation, it seems possible that by
controlling parasite densities during malaria infections [27]
innate processes might paradoxically increase the chronicity
of individual infections. This hypothesis is supported by the
greater number of strains of P. falciparum parasites found in
HbAS than HbAA children at cross-sectional survey [28]. By
increasing the duration of individual malaria infections
HbAS might paradoxically increase host exposure to a variety
of antigens capable of inducing malaria-speciﬁc immunity.
Determining which if any of these mechanisms are involved
could lead to a better understanding of malaria immunity
more generally.
In our current study we have focused on mild clinical
malaria. For accelerated malaria-speciﬁc immunity to be
relevant to HbAS selection it would have to operate within
the period of maximum risk for severe and fatal malaria. In
Kiliﬁ, this risk is greatest in children less than 5 y old [29]. It is
clear from a recent study conducted in western Kenya [4] that
HbAS is strongly protective against severe and fatal malaria
within this age range; however, protection by HbAS against
both severe malaria anaemia and all-cause mortality was only
seen in the age range 2–16 mo. The authors suggested that
this may have reﬂected early protection by maternally
transferred immunoglobulins followed by the general acquis-
ition of protective immunity after the age of 16 mo; however,
they presented no data regarding the effect of age between
these extremes. Given the level of protection conferred by
HbAS against severe malaria, it is possible that their study was
not sufﬁciently powered to address this question. The
relevance of our observations in mild clinical malaria to the
protection afforded by HbAS against severe and fatal malaria
therefore remains unknown. While immunity against severe
malaria develops signiﬁcantly more rapidly than immunity to
mild clinical attacks, the determinants of each remain poorly
understood. We suggest that establishing the role of HbAS in
each of these processes may be one route to learning more
about the mechanisms involved.
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Patient Summary
Background Sickle cell anemia, which is caused by having two copies of
an abnormal gene (hemoglobin S—HbS) that causes red cells to deform
easily, occurs more frequently in populations exposed to malaria.
Previous work has shown that carrying one normal copy of the gene
(HbA) and one copy of the version responsible for sickle cell disease (the
combination is called HbAS) may protect against getting malaria; hence,
this abnormal gene provides an advantage to some people who carry it.
How this protection happens is unclear, but may be due to changes in
the way that people with HbAS develop immunity to malaria.
What Did the Authors Do? One way of working out whether acquired
immunity is important in how HbAS protects against malaria is to look at
a large population with many different age ranges, all exposed to
malaria, and measure how often these individuals get malaria. The
authors of this paper looked at 1,054 people in Kenya with an age range
from birth up to 84 years, but predominantly aged less than 10 years,
who either had HbAS or normal hemoglobin (HbAA). They found that
protection of HbAS against mild malaria increased with age from 20% in
the first two years of life to a maximum of 56% by the age of ten years,
and then decreased to 30% in people older than ten years.
What Do These Findings Mean? The presence of HbAS is associated
with increased acquired immunity to mild malaria. Further work will
need to be done to work out how this change in immunity occurs. It is
not yet known whether these results are also true for protection against
severe malaria, and in any case the protection is only partial; hence,
treatment of anyone with malaria, whatever their sickle cell status, is
essential.
Where Can I Get More Information? The Centers for Disease Control
and Prevention publish reviews of various conditions. The one on sickle
cell disease includes links to other sources of information: http://
www.cdc.gov/genomics/hugenet/reviews/sickle.htm
The World Health Organization has a Web page on malaria: http://
www.who.int/topics/malaria/en/
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